SBFM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SBFM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-08), the Trailing Annual Dividend Yield of Sunshine Biopharma is 0.00%.
The historical rank and industry rank for Sunshine Biopharma's Dividend Yield % or its related term are showing as below:
Sunshine Biopharma's Dividend Payout Ratio for the three months ended in Mar. 2024 was 0.00.
As of today (2024-06-08), the Forward Dividend Yield % of Sunshine Biopharma is 0.00%.
Sunshine Biopharma's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
The historical data trend for Sunshine Biopharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
Sunshine Biopharma Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Dividend Yield % | Get a 7-Day Free Trial | - | - | - | - | - |
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Sunshine Biopharma (NAS:SBFM) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Sunshine Biopharma's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Camille Sebaaly | director, officer: CFO and Secretary | 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1 |
Malek Chamoun | 10 percent owner | 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2 |
David Natan | director | 11190 BISCAYNE BLVD, MIAMI FL 33181 |
Andrew Mark Keller | director | 10 ISLAND DRIVE, NORWALK CT 06855 |
Andrew I Telsey | director | 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111 |
James Daniel Kish | director | 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111 |
Rabi Kiderchah | director | 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3 |
Advanomics Corp | 10 percent owner | 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
Steve N. Slilaty | director, 10 percent owner, officer: CEO and President | 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4 |
Abderrazzak Merzouki | director, officer: Chief Operating Officer | 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1 |
Turi Michele Di | director, officer: Chief Operating Officer | 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 02-17-2022
By PurpleRose PurpleRose • 08-04-2022
By GuruFocusNews GuruFocusNews • 02-25-2022
By sperokesalga sperokesalga • 02-10-2023
By GuruFocus Research GuruFocus Editor • 12-02-2022
By PurpleRose PurpleRose • 07-28-2022
By ACCESSWIRE ACCESSWIRE • 02-10-2021
By ACCESSWIRE ACCESSWIRE • 01-27-2021
By ACCESSWIRE ACCESSWIRE • 05-16-2023
By GuruFocusNews GuruFocusNews • 04-28-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.